Zacks: Analysts Expect Minerva Neurosciences Inc (NASDAQ:NERV) Will Announce Earnings of -$0.41 Per Share

Wall Street analysts expect Minerva Neurosciences Inc (NASDAQ:NERV) to report earnings of ($0.41) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Minerva Neurosciences’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.49). Minerva Neurosciences reported earnings of ($0.34) per share in the same quarter last year, which indicates a negative year over year growth rate of 20.6%. The business is expected to report its next quarterly earnings results on Tuesday, March 10th.

On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.58) to ($1.44). For the next fiscal year, analysts forecast that the company will report earnings of ($1.69) per share, with EPS estimates ranging from ($3.32) to ($0.91). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.01.

NERV has been the subject of several research reports. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price objective on shares of Minerva Neurosciences in a research note on Tuesday, October 1st. BidaskClub raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 23rd. Zacks Investment Research cut Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. ValuEngine lowered Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 30th. Finally, William Blair started coverage on Minerva Neurosciences in a report on Wednesday, September 18th. They issued an “outperform” rating and a $26.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.44.

NERV traded up $0.16 on Friday, reaching $5.72. 467,047 shares of the company’s stock were exchanged, compared to its average volume of 381,390. The stock has a market cap of $201.37 million, a PE ratio of -4.43 and a beta of 1.50. Minerva Neurosciences has a twelve month low of $4.01 and a twelve month high of $9.12. The stock’s fifty day moving average price is $4.73 and its 200-day moving average price is $6.03.

Institutional investors have recently added to or reduced their stakes in the stock. Quantitative Systematic Strategies LLC acquired a new stake in Minerva Neurosciences during the second quarter worth $62,000. TD Asset Management Inc. boosted its stake in Minerva Neurosciences by 2.8% during the second quarter. TD Asset Management Inc. now owns 58,847 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 1,600 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at about $355,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Minerva Neurosciences during the second quarter valued at about $464,000. Finally, Acadian Asset Management LLC increased its position in shares of Minerva Neurosciences by 75.1% during the second quarter. Acadian Asset Management LLC now owns 58,024 shares of the biopharmaceutical company’s stock valued at $326,000 after acquiring an additional 24,890 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Further Reading: What is meant by holder of record?

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.